Drilldown: Medicines

None (2) · Famotidine (1)

Ajovy (1) · Emgality (1) · Pepcid, Pepcid AC, Pepcid Complete (1)

Anti-CGRP ligand monoclonal antibody (2) · [[:Category:Antisecretory_agents|Gastric acid suppressant]] (1) · [[:Category:H2_receptor_antagonists|Histamine H2 receptor antagonist]] (1)

Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) · '"`UNIQ--vote-00000255-QINU`"' Less potent and shorter-acting than PPIs but with faster on-effect; suitable for on-demand acid suppression. Largely renally cleared; dose-adjust in renal impairment to avoid CNS effects (confusion in elderly)'"`UNIQ--ref-00000256-QINU`"'. (1)

Preventive treatment of migraine in adults (episodic and chronic) (1) · Preventive treatment of migraine in adults; episodic cluster headache (1) · '"`UNIQ--vote-00000257-QINU`"', '"`UNIQ--vote-00000258-QINU`"', '"`UNIQ--vote-00000259-QINU`"', '"`UNIQ--vote-0000025A-QINU`"' (1)

20 mg PO twice daily, or 40 mg at bedtime (1) · 225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)

10 mg, 20 mg, 40 mg tablets; chewables; 40 mg/5 mL oral suspension; 10 mg/mL IV (1) · 120 mg/mL prefilled syringe or autoinjector (1) · 225 mg/1.5 mL prefilled syringe or autoinjector (1)

160 mg/d (Zollinger-Ellison); 80 mg/d for routine indications (1) · 240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 675 mg/quarter (1)

IV (1) · Oral (1) · Subcutaneous (2)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

6-12 hours (1) · Monthly dosing (1) · Monthly or quarterly dosing (1)

2.5-3.5 hours; longer in renal impairment'"`UNIQ--ref-0000025B-QINU`"' (1) · ~27 days (1) · ~31 days (1)

40-45% (oral; not significantly affected by food)'"`UNIQ--ref-0000025C-QINU`"' (1) · Not formally established (1) · Not formally established (high SC) (1)

Generally considered safe; widely used. Cleared in lactation at low levels.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited data; avoid (2)

OTC (10-20 mg) and [[USLegal:Prescription only|Rx-only]] (higher doses) in US (1) · Rx (2)